

The Daily

December 20, 2023









DOMESTIC INDICES						
CLOSE POINTS % CHAN						
SENSEX	71437	122	0.17			
NIFTY	21453	34	0.16			
MIDCAP	36186	-114	-0.31			
SMALL CAP	42328	42	0.10			

SECTORAL INDICES						
	CLOSE	POINTS	% CHANGE			
OIL & GAS	22405	103	0.46			
CD	49053	209	0.43			
METAL	26040	103	0.40			
POWER	5800	22	0.39			
HEALTHCARE	30680	86	0.28			
BANKEX	54083	61	0.11			
FINANCE	10445	-5	-0.05			
CG	54739	-161	-0.29			
REALTY	5966	-35	-0.58			
AUTO	40885	-283	-0.69			
TECK	15842	-129	-0.81			
IT	35974	-303	-0.84			

BSE 200 GAINERS/LOSERS						
GAINERS	GAINERS % LOSERS					
IRFC	6.13	SAIL	-3.88			
OIL	5.79	ZEEL	-3.17			
COALINDIA	5.57	LTTS	-3.05			
NESTLEIND	4.66	SIEMENS	-2.89			
IOB	4.11	MAXHEALTH	-2.69			

ADVANCE/DECLINES					
BSE %					
ADVANCES	1895	49			
DECLINES	1866	48			
UNCHANGED	143	4			

INSTITUTIONAL ACTIVITY							
Rs Cr	Rs Cr 18-12-2023 19-12-2023 DEC TO						
FII	-34	-602	29097				
DII	414	294	3890				

Indian markets could open higher, in line with mostly higher Asian markets today and positive US markets on Dec 19.

U.S. stocks closed higher Tuesday, with the Dow Jones Industrial Average notching a fifth straight record close and the S&P 500 closing just shy of its peak, as investors keep cheering the chances of Federal Reserve rate cuts next year and an economy that keeps chugging along.

November housing starts in the US increased 14.8% after a revised 0.2% gain for October. That's the best reading since May.

In Bank of America's latest look at fund-manager sentiment, managers had their rosiest view of the stock market since January 2022 — right around the S&P 500's record close.

Most markets in the Asia-Pacific region rose, tracking overnight gains on Wall Street as traders continued to remain optimistic about the U.S. Federal Reserve cutting interest rates in 2024 and Japan stocks extending gains to another session after the country's central bank left its ultra-loose monetary policy unchanged at its final meeting this year. The People's Bank of China held its one-year loan prime rate — the peg for most household and corporate loans in the country — at 3.45%. The five-year benchmark loan rate — the peg for most mortgages — was unchanged at 4.2%.

Nifty ended with marginal gains on Tuesday after a weak morning session. A strong recovery from the lows helped the index to close in the green. Nifty finally gained 34.45 points or 0.16% to close at 21,453.1. Markets seem to be consolidating in a range for the last two sessions. Further directional cues are likely to emerge on a move beyond the 21337-21595 trading range.

Bharat Petroleum Corporation Ltd approves setting up of new Polypropylene unit

Bharat Petroleum Corporation Limite has approved a proposal for setting up Polypropylene (PP) Unit, for production of 400 Kilo-Tonnes Per Annum Polypropylene at Kochi Refinery, at gross project cost of Rs. 5044 crore. Considering the robust growth due to expanding market demand of the petrochemical segment in India and availability of Propylene feedstock provides BPCL Kochi Refinery (KR) opportunities for production of Polypropylene, which has wide applications in downstream industries such as Packaging Films, Sheet, Boxes, Containers, Bags, Home Ware, Home Care, Personal Care and articles of day-to-day usage.







GLOBAL INDICES						
	CLOSE	POINTS	% CHANGE			
DOW JONES	37558	251.90	0.68			
S & P 500	4768	27.81	0.59			
NASDAQ	16812	82.05	0.49			
FTSE	7638	23.55	0.31			
CAC	7575	5.81	0.08			
DAX	16744	93.86	0.56			
NIKKEI	33805	585.11	1.76			
SHANGHAI	2928	-4.69	-0.16			
HANG SENG	16724	202.00	1.22			
BOVESPA	131851	767.00	0.59			

EXCHANGE RATES						
VALUE % CHANGE						
USD/INR	83.2	0.20				
EURO/USD	1.097	-0.10				
USD/GBP	1.272	-0.08				
USD/JPY	143.9	0.08				

COMMODITIES							
	% CHANGE						
GOLD (\$ / Oz)	2053.1	0.05					
SILVER (\$ / Oz)	24.4	0.30					
CRUDE OIL FUTURES	74.1	0.19					
BRENT OIL (\$ / Barrel)	79.3	-0.08					

BOND YIELD					
	VALUE	ABS CHANGE			
IND10 YEAR BOND YIELD	7.171	+0.018			

ADR					
	VALUE	% CHANGE			
DR REDDY'S LAB	68.1	1.38			
HDFC BANK	66.2	0.09			
ICICI BANK	24.5	-0.16			
TATA MOTORS	25.1	0.00			
WIPRO	5.27	-0.85			
VEDANTA LTD	16.50	0.00			
INFOSYS	18.78	-0.11			

LTIMindtree Collaborates with Microsoft to Deliver Al Powered Employee Engagement Applications

LTIMindtree announced a strategic collaboration with Microsoft to introduce cutting-edge, AI Powered Employee Engagement Applications. This collaboration marks a significant leap forward in delivering enhanced employee and customer experiences. Under the umbrella of LTIMindtree's innovative Canvas.AI suite of AI offerings and solutions, these Generative AI Powered Employee Engagement Applications will redefine enterprise effectiveness and enable greater personalization.

Bids for another 100 critical mineral blocks in February 2024: Mines Minister Pralhad Joshi

The Indian government plans to call bids for an additional 100 critical mineral blocks in February 2024, as part of the second round of auctions, according to Mines Minister Pralhad Joshi. Bids have already been invited for 20 critical mineral-bearing blocks. India recently identified 24 minerals as strategic and critical for the country, including graphite, molybdenum, lithium, and platinum group elements.

Delhi HC orders CBI & DRI to investigate allegations of overinvoicing by companies including Adani, Essar Groups

Delhi High Court on Tuesday directed the CBI and DRI to meticulously and expeditiously look into the allegations of over invoicing of coal imports and equipment by several companies, including Adani Group and Essar Group, and take action in accordance with law.

JB Chemicals & Pharma entered into Ophthalmology segment

JB Chemicals & Pharmaceuticals Ltd (JB Pharma) approved the execution of a Trade-Mark License Agreement with Novartis Innovative Therapies AG, Switzerland which is perpetual in nature, for a portfolio of ophthalmology brands for the India market which will be effective from January 2027 for a consideration of US\$ 116mn payable on or before 31st December 2026.

It would be at US\$ 116 million (~Rs 964 crore) (excluding applicable taxes, stamp duty and working capital) for the Trade Marks License Agreement to Novartis Innovative Therapies AG, Switzerland. Rs 125 crore (excluding applicable taxes, stamp duty and working capital) under the Promotion and Distribution Agreement to Novartis Healthcare Private Limited, India.







As per IQVIA, MAT September, 2023, sales for this ophthalmology portfolio stood at Rs 207.8 crore Key brands include Azopt, Travatan, Simbrinza, Travacom, Vigamox and Nevanac.

Deepak Nitrate subsidiary to supply propylene and hydrogen to Petronet LNG

A wholly-owned subsidiary of Deepak Nitrite announced that it will supply propylene and hydrogen to Petronet LNG. The wholly-owned subsidiary, Deepak Phenolics Limited, will supply 250 kilotons per annum (KTPA) of propylene and 11 KTPA of hydrogen from its Petronet Petrochemical Project in Dahej, Gujarat, as stated by Deepak Nitrate in an exchange filing. For this, the boards of both companies approved a binding term sheet.

The arrangement spans 15 years from the initial delivery of propylene and hydrogen. A Definitive Agreement will be formalized in due course, solidifying this strategic partnership between DPL and PLL in the realm of chemical off-take.

Varun Beverages to acquire PepsiCo's South Africa bottler Bevco

Varun Beverages Ltd (VBL), one of PepsiCo's largest franchise bottlers worldwide, announced the acquisition of South Africa-based Beverage Company (Bevco) along with its wholly-owned subsidiaries at an enterprise value of Rs 1,320 crore.

The proposed transaction is valued at an enterprise level of ZAR 3 billion (Rs 1,320 crore) and will help it expand its geographical footprint in the African market.

RVNL JV emerges as the lowest bidder

RVNL emerged as the lowest bidder for a project worth Rs 123 crore in a 49:51 Joint venture with KRDCL. The project is to upgrade Varkala Sivagiri railway station in Kerala.

Nippon Life India AMC bulk deal update

IndusInd Bank will sell a 2.86% stake in NAM India via a block deal today. The floor size is set at Rs 426 per share, 5% discount to closing price.

JK Tyre and Industries launches QIP issue to raise Rs 500 crore

The company opened its QIP for raising up to Rs 500 crore, and has set the floor price of QIP at Rs 358.96 per share which indicates a discount of 5.2% to the stock's previous close of Rs 378.70.







Important news/developments to influence markets

US Building Permits Fall More than Expected

Building permits in the United States fell by 2.5% to a seasonally adjusted annual rate of 1.460 million in November 2023, below market expectations of 1.470 million, preliminary data showed.

Japan Trade Gap Plunges

Japan's trade deficit decreased sharply to JPY 776.94 billion in November 2023 from JPY 2,057,64 billion in the same month of the prior year, compared with market estimates of a shortfall of JPY 962.4 billion.

Bank of Japan Holds Rates

The Bank of Japan maintained its key short-term interest rate at -0.1% and that of 10-year bond yields at around 0% in a final meeting of the year by unanimous vote, as widely expected.

Euro Area Inflation Rate Confirmed at 2.4%

Annual inflation rate in the Euro Area decreased to 2.4% in November 2023, the lowest since July 2021, from 2.9% in October and in line with the preliminary release.







Index	СМР	View	R1	R2	S1	S2
Nifty Dec Fut	21527	Bullish	21609	21692	21430	21332
BankNifty Dec Fut	48009	Bullish	48230	48450	47787	47564





Daily Technical View on Nifty

- ✓ Nifty recovered 168 points from the day's low of 21337 and hit fresh all time high of 21505.
- ✓ Nifty ended the session off the highs and settled with 34 points gain at 21453.
- ✓ Nifty continue to remain in bullish trend and holding longs with trailing stoploss is the ideal strategy.
- ✓ 5 days EMA is placed near 21300 and same is expected to act as a support going forward.
- ✓ Resistance for the Nifty is seen in the zone of 21500-21600, where call writing has been happening in the derivative side.
- ✓ As per the seasonality, December has been the best month for the Nifty and as in this month till date, index has risen more than 6%.
- ✓ Oscillators have reached the overbought zone on daily and weekly charts for Nifty.
- ✓ However, unless important support breaks on the price charts, trend reversal would not be confirmed.
- ✓ So, it would be advisable to hold on the longs with the trailing stoploss for index and stocks.
- ✓ Positionally on the upside, next target for Nifty is seen at 22231, which happens to be 100% extension level of the entire swing seen from March 2023 bottom (16828) to Sep 2023 top (20222) and from Sep 2023 top (20222) to October 2023 bottom(18837).





OPEN SHORT-TERM TRADING CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	СМР	SL	TARGET	UPSIDE %	VALID TILL
1	19-DEC-23	BUY	BANK NIFTY DEC FUT	48188.55-47980	48,000.00	47,880.0	48,600.0	1.3	22-DEC-23
2	14-DEC-23	BUY	BAJAJ FINANCE DEC FUT	7514.20-7395	7,659.90	7,295.0	7,840.0	2.4	28-DEC-23
3	4-DEC-23	BUY	GREAVES COTTON	138.50-133.80	140.05	131.9	146.0	4.2	28-DEC-23
4	7-DEC-23	BUY	AVTNPL	94.30-92	94.20	90.8	101.0	7.2	21-DEC-23
5	12-DEC-23	BUY	REDINGTON	173.90-169	175.40	165.5	184.0	4.9	26-DEC-23
6	14-DEC-23	BUY	ADVENZYMES	369-362	374.80	357.5	395.0	5.4	28-DEC-23
7	18-DEC-23	BUY	ZYDUS LIFE	660-670.70	685.85	645.0	705.5	2.9	1-JAN-24
8	19-DEC-23	BUY	NOCIL	271.10-264	273.60	258.0	293.0	7.1	2-JAN-24

OPEN E-MARGIN POSITIONAL CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	СМР	SL	TARGET 1	TARGET 2	UPSIDE %	VALID TILL
1	13-NOV-23	BUY	NCC*	156-162.65	166.1	162.7	174.0	184.0	11	13-FEB-24
2	16-NOV-23	BUY	DREAMFOLKS	530-550.90	554.9	505.0	597.0	650.0	17	16-FEB-24
3	17-NOV-23	BUY	RVNL*	156-164.35	183.9	164.4	177.0	194.0	6	17-FEB-24
4	21-NOV-23	BUY	BASF	2943-3066	3059.7	2882.0	3280.0	3525.0	15	21-FEB-24
5	21-NOV-23	BUY	EPL LTD	190-200.50	200.9	184.0	218.0	235.0	17	21-FEB-24
6	22-NOV-23	BUY	GLAND PHARMA*	1650- 1704.35	1859.0	1704.0	1810.0	1890.0	2	22-JAN-24
7	6-DEC-23	BUY	SHYAM METALICS*	496.85-471	539.6	496.9	542.0	575.0	7	6-MAR-24
8	6-DEC-23	BUY	ITC	450-459.65	456.1	433.0	491.8	520.0	14	6-FEB-24
9	6-DEC-23	BUY	ROSSARI BIOTECH	753-791.05	808.0	722.0	890.0	925.0	14	6-MAR-24
10	11-DEC-23	BUY	KARURVYSYA BANK *	150-158	168.7	158.0	172.0	185.0	10	11-MAR-24
11	12-DEC-23	BUY	RITES	485-497.60	515.9	470.0	532.0	580.0	12	12-MAR-24
12	12-DEC-23	BUY	GSFC	212-225.20	230.9	206.0	247.0	270.0	17	12-FEB-24
13	12-DEC-23	BUY	EQUITAS BANK*	94.50-98.50	105.6	92.6	105.5	113.5	8	12-MAR-24
14	13-DEC-23	BUY	NAZARA TECH*	808.40- 842.35	875.2	842.4	901.5	968.0	11	13-MAR-24
15	13-DEC-23	BUY	VEDL	243-253.75	262.1	235.0	275.0	295.0	13	13-FEB-24
16	14-DEC-23	BUY	STAR CEMENT	165-174.10	176.8	160.0	188.0	210.0	19	14-MAR-24
17	15-DEC-23	BUY	GODREJ AGRO	544.70-520	560.2	501.0	598.0	630.0	12	15-MAR-24
18	18-DEC-23	BUY	SCI	151-163.40	169.1	145.0	182.0	199.0	18	18-MAR-24

^{*= 1}st Target Achieved







Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may, (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.



#HDFCsecMythBusters





Scan the code to download our mobile app now!

Global Investing, Basket Investing are not a Exchange traded product and all disputes related to the distribution activity of Global Investing and Basket Investing will not have access to Exchange investor redressal forum or Arbitration mechanism. Involvement of HDFC securities is restricted to Referral only. HDFC securities does not offer this product directly to customers https://www.hdfcsec.com/globalinvesting. Account would be opened after all procedure relating to IPV and client due diligence is completed. Investment in securities market are subject to market risks, read all the related documents carefully before investing. SEBI registration & disclaimers: https://www.hdfcsec.com/article/disclaimer-1795. The information is only for consumption by the client and such material should not be redistributed.